FT819 in Subjects With B-cell Malignancies
Is a
Allocation Type
Non-Randomized
0
Intervention Model
Sequential Assignment
0
Intervention Name
Bendamustine
0
IL-2
0
Fludarabine
0
FT819
0
Cyclophosphamide
0
Interventional Trial Phase
Phase 1
0
Interventional Trial Purpose
Treatment
0
Intervention Type
Drug
0
Last Updated
November 2, 2023
0
Masking Type
None (Open Label)
0
Primary Completion Date
September 30, 2024
0
Trial Recruitment Size
396
0
Trial Sponsor
Clinical Trial Start Date
July 26, 2021
0
Study Completion Date
September 30, 2039
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
A Phase I Study of FT819 in Subjects With B-cell Malignancies
0
Official Website
Find more entities like FT819 in Subjects With B-cell Malignancies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.